Paradoxical roles of dual oxidases in cancer biology

Free Radical Biology and Medicine

Volumn 110, Issue , 2017, Pages 117-132

  Little, Andrew C ^a,b   Sulovari, Arvis ^a,b   Danyal, Karamatullah ^a   Heppner, David E ^a   Seward, David J ^a   van der Vliet, Albert ^a,b  

^a UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF VERMONT   (United States)

Author keywords

DUOX; EGFR; Epigenetics; Epithelial; NADPH oxidase; NOX; Reactive oxygen species

Indexed keywords

DUAL OXIDASE; DUAL OXIDASE 1; DUAL OXIDASE 2; OXIDOREDUCTASE; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 1; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 2; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 4; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 5; UNCLASSIFIED DRUG; DUOX1 PROTEIN, HUMAN; DUOX2 PROTEIN, HUMAN;

AEROBIC METABOLISM; BREAST CANCER; CELL COMMUNICATION; CELL MIGRATION; CELL PROLIFERATION; COLORECTAL CANCER; ENZYME ACTIVATION; ENZYME ACTIVITY; ESOPHAGUS CANCER; GENE SILENCING; HAIRY CELL LEUKEMIA; HUMAN; LUNG CANCER; MALIGNANT NEOPLASM; MITOCHONDRIAL RESPIRATION; MYELOMONOCYTIC LEUKEMIA; NONHUMAN; PANCREAS ADENOCARCINOMA; PENTOSE PHOSPHATE CYCLE; PHAGOCYTE; PRIORITY JOURNAL; RECTUM CANCER; REVIEW; SIGNAL TRANSDUCTION; STOMACH CANCER; UPREGULATION; ANIMAL; CLASSIFICATION; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; NEOPLASM; OXIDATION REDUCTION REACTION; OXIDATIVE STRESS; PATHOLOGY; TUMOR INVASION;

ANIMALS; DUAL OXIDASES; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; NEOPLASM INVASIVENESS; NEOPLASMS; OXIDATION-REDUCTION; OXIDATIVE STRESS; REACTIVE OXYGEN SPECIES; SIGNAL TRANSDUCTION;

EID: 85020475760     PISSN: 08915849     EISSN: 18734596     Source Type: Journal    
DOI: 10.1016/j.freeradbiomed.2017.05.024     Document Type: Review

References (272)

1. [1] Lambeth, J.D., NOX enzymes and the biology of reactive oxygen. Nat. Rev. Immunol. 4:3 (2004), 181–189.
2. [2] Lambeth, J.D., Neish, A.S., Nox enzymes and new thinking on reactive oxygen: a double-edged sword revisited. Annu. Rev. Pathol. 9 (2014), 119–145.
3. [3] Holmstrom, K.M., Finkel, T., Cellular mechanisms and physiological consequences of redox-dependent signalling. Nat. Rev. Mol. Cell Biol. 15:6 (2014), 411–421.
4. [4] Reczek, C.R., Chandel, N.S., ROS-dependent signal transduction. Curr. Opin. Cell Biol. 33 (2015), 8–13.
5. [5] Janssen-Heininger, Y.M., Mossman, B.T., Heintz, N.H., Forman, H.J., Kalyanaraman, B., Finkel, T., Stamler, J.S., Rhee, S.G., van der Vliet, A., Redox-based regulation of signal transduction: principles, pitfalls, and promises. Free Radic. Biol. Med. 45:1 (2008), 1–17.
6. [6] Chandrasekaran, A., Idelchik, M.D., Melendez, J.A., Redox control of senescence and age-related disease. Redox Biol. 11 (2016), 91–102.
7. [7] Fakhruddin, S., Alanazi, W., Jackson, K.E., Diabetes-induced reactive oxygen species: mechanism of their generation and role in renal injury. J. Diabetes Res., 2017, 2017, 8379327.
8. [8] Forstermann, U., Xia, N., Li, H., Roles of vascular oxidative stress and nitric oxide in the pathogenesis of atherosclerosis. Circ. Res. 120:4 (2017), 713–735.
9. [9] S. Galadari, A. Rahman, S. Pallichankandy, F. Thayyullathil, Reactive oxygen species and cancer paradox: to promote or to suppress?, Free Radic. Biol. Med.
10. [10] Landry, W.D., Cotter, T.G., ROS signalling, NADPH oxidases and cancer. Biochem. Soc. Trans. 42:4 (2014), 934–938.
11. [11] Prasad, S., Gupta, S.C., Tyagi, A.K., Reactive oxygen species (ROS) and cancer: role of antioxidative nutraceuticals. Cancer Lett. 387 (2017), 95–105.
12. [12] DeBerardinis, R.J., Chandel, N.S., Fundamentals of cancer metabolism. Sci. Adv., 2(5), 2016, e1600200.
13. [13] Block, K., Gorin, Y., Aiding and abetting roles of NOX oxidases in cellular transformation. Nat. Rev. Cancer 12:9 (2012), 627–637.
14. [14] Roy, K., Wu, Y., Meitzler, Jennifer L., Juhasz, A., Liu, H., Jiang, G., Lu, J., Antony, S., Doroshow, James H., NADPH oxidases and cancer. Clin. Sci. 128:12 (2015), 863–875.
15. [15] Al-Tonbary, Y., Al-Haggar, M., El-Ashry, R., El-Dakroory, S., Azzam, H., Fouda, A., Vitamin e and N-acetylcysteine as antioxidant adjuvant therapy in children with acute lymphoblastic leukemia. Adv. Hematol., 2009, 2009, 689639.
16. [16] Pathak, A.K., Bhutani, M., Guleria, R., Bal, S., Mohan, A., Mohanti, B.K., Sharma, A., Pathak, R., Bhardwaj, N.K., Prasad, K.N., Kochupillai, V., Chemotherapy alone vs. chemotherapy plus high dose multiple antioxidants in patients with advanced non small cell lung cancer. J. Am. Coll. Nutr. 24:1 (2005), 16–21.
17. [17] Yoo, J., Hamilton, S.J., Angel, D., Fung, K., Franklin, J., Parnes, L.S., Lewis, D., Venkatesan, V., Winquist, E., Cisplatin otoprotection using transtympanic L-N-acetylcysteine: a pilot randomized study in head and neck cancer patients. Laryngoscope 124:3 (2014), E87–E94.
18. [18] Smyth, J.F., Bowman, A., Perren, T., Wilkinson, P., Prescott, R.J., Quinn, K.J., Tedeschi, M., Glutathione reduces the toxicity and improves quality of life of women diagnosed with ovarian cancer treated with cisplatin: results of a double-blind, randomised trial. Ann. Oncol.: Off. J. Eur. Soc. Med. Oncol. 8:6 (1997), 569–573.
19. [19] Schmidinger, M., Budinsky, A.C., Wenzel, C., Piribauer, M., Brix, R., Kautzky, M., Oder, W., Locker, G.J., Zielinski, C.C., Steger, G.G., Glutathione in the prevention of cisplatin induced toxicities. A prospectively randomized pilot trial in patients with head and neck cancer and non small cell lung cancer. Wien. Klin. Wochenschr. 112:14 (2000), 617–623.
20. [20] Colombo, N., Bini, S., Miceli, D., Bogliun, G., Marzorati, L., Cavaletti, G., Parmigiani, F., Venturino, P., Tedeschi, M., Frattola, L., Buratti, C., Mangioni, C., Weekly cisplatin +/- glutathione in relapsed ovarian carcinoma. Int. J. Gynecol. Cancer: Off. J. Int. Gynecol. Cancer Soc. 5:2 (1995), 81–86.
21. [21] Cascinu, S., Catalano, V., Cordella, L., Labianca, R., Giordani, P., Baldelli, A.M., Beretta, G.D., Ubiali, E., Catalano, G., Neuroprotective effect of reduced glutathione on oxaliplatin-based chemotherapy in advanced colorectal cancer: a randomized, double-blind, placebo-controlled trial. J. Clin. Oncol.: Off. J. Am. Soc. Clin. Oncol. 20:16 (2002), 3478–3483.
22. [22] Cascinu, S., Cordella, L., Del Ferro, E., Fronzoni, M., Catalano, G., Neuroprotective effect of reduced glutathione on cisplatin-based chemotherapy in advanced gastric cancer: a randomized double-blind placebo-controlled trial. J. Clin. Oncol.: Off. J. Am. Soc. Clin. Oncol. 13:1 (1995), 26–32.
23. [23] Le Gal, K., Ibrahim, M.X., Wiel, C., Sayin, V.I., Akula, M.K., Karlsson, C., Dalin, M.G., Akyurek, L.M., Lindahl, P., Nilsson, J., Bergo, M.O., Antioxidants can increase melanoma metastasis in mice. Sci. Transl. Med., 7(308), 2015, 308re8.
24. [24] Sayin, V.I., Ibrahim, M.X., Larsson, E., Nilsson, J.A., Lindahl, P., Bergo, M.O., Antioxidants accelerate lung cancer progression in mice. Sci. Transl. Med., 6(221), 2014, 221ra15.
25. [25] Glasauer, A., Sena, L.A., Diebold, L.P., Mazar, A.P., Chandel, N.S., Targeting SOD1 reduces experimental non-small-cell lung cancer. J. Clin. Investig. 124:1 (2014), 117–128.
26. [26] Wondrak, G.T., Redox-directed cancer therapeutics: molecular mechanisms and opportunities. Antioxid. Redox Signal. 11:12 (2009), 3013–3069.
27. [27] Gonzalez, M.J., Rosario-Perez, G., Guzman, A.M., Miranda-Massari, J.R., Duconge, J., Lavergne, J., Fernandez, N., Ortiz, N., Quintero, A., Mikirova, N., Riordan, N.H., Ricart, C.M., Mitochondria, energy and cancer: the relationship with ascorbic acid. J. Orthomol. Med.: Off. J. Acad. Orthomol. Med. 25:1 (2010), 29–38.
28. [28] Keishla, C.D.J., Garcia, M., Berdiel, Miguel J., Miranda Massari, Jorge R., Duconge, Jorge, Gonzalez, Michael J., Intravenous vitamin C and metabolic correction as adjuvant therapy for prostate cancer: a case report. J. Cancer Prev. Curr. Res., 5(3), 2016, 00164.
29. [29] Schoenfeld, J.D., Sibenaller, Z.A., Mapuskar, K.A., Wagner, B.A., Cramer-Morales, K.L., Furqan, M., Sandhu, S., Carlisle, T.L., Smith, M.C., Abu Hejleh, T., Berg, D.J., Zhang, J., Keech, J., Parekh, K.R., Bhatia, S., Monga, V., Bodeker, K.L., Ahmann, L., Vollstedt, S., Brown, H., Shanahan Kauffman, E.P., Schall, M.E., Hohl, R.J., Clamon, G.H., Greenlee, J.D., Howard, M.A., Shultz, M.K., Smith, B.J., Riley, D.P., Domann, F.E., Cullen, J.J., Buettner, G.R., Buatti, J.M., Spitz, D.R., Allen, B.G., O2⋅- and H2O2-mediated disruption of Fe metabolism causes the differential susceptibility of NSCLC and GBM cancer cells to pharmacological ascorbate. Cancer Cell 31:4 (2017), 487–500 (e8).
30. [30] Saybasili, H., Yuksel, M., Haklar, G., Yalcin, A.S., Effect of mitochondrial electron transport chain inhibitors on superoxide radical generation in rat hippocampal and striatal slices. Antioxid. Redox Signal. 3:6 (2001), 1099–1104.
31. [31] Li, L., Fath, M.A., Scarbrough, P.M., Watson, W.H., Spitz, D.R., Combined inhibition of glycolysis, the pentose cycle, and thioredoxin metabolism selectively increases cytotoxicity and oxidative stress in human breast and prostate cancer. Redox Biol. 4 (2015), 127–135.
32. [32] Vander Heiden, M.G., Cantley, L.C., Thompson, C.B., Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 324:5930 (2009), 1029–1033.
33. [33] DeBerardinis, R.J., Chandel, N.S., Fundamentals of cancer metabolism. Sci. Adv., 2(5), 2016, e1600200.
34. [34] Lee, N., Kim, D., Cancer metabolism: fueling more than just growth. Mol. Cells 39:12 (2016), 847–854.
35. [35] Weinberg, F., Hamanaka, R., Wheaton, W.W., Weinberg, S., Joseph, J., Lopez, M., Kalyanaraman, B., Mutlu, G.M., Budinger, G.R., Chandel, N.S., Mitochondrial metabolism and ROS generation are essential for Kras-mediated tumorigenicity. Proc. Natl. Acad. Sci. USA 107:19 (2010), 8788–8793.
36. [36] Wheaton, W.W., Weinberg, S.E., Hamanaka, R.B., Soberanes, S., Sullivan, L.B., Anso, E., Glasauer, A., Dufour, E., Mutlu, G.M., Budigner, G.S., Chandel, N.S., Metformin inhibits mitochondrial complex I of cancer cells to reduce tumorigenesis. eLife, 3, 2014, e02242.
37. [37] Orr, A.L., Vargas, L., Turk, C.N., Baaten, J.E., Matzen, J.T., Dardov, V.J., Attle, S.J., Li, J., Quackenbush, D.C., Goncalves, R.L., Perevoshchikova, I.V., Petrassi, H.M., Meeusen, S.L., Ainscow, E.K., Brand, M.D., Suppressors of superoxide production from mitochondrial complex III. Nat. Chem. Biol. 11:11 (2015), 834–836.
38. [38] Diebold, L., Chandel, N.S., Mitochondrial ROS regulation of proliferating cells. Free Radic. Biol. Med. 100 (2016), 86–93.
39. [39] Murphy, M.P., Modulating mitochondrial intracellular location as a redox signal. Sci. Signal., 5(242), 2012, pe39.
40. [40] Bonner, M.Y., Arbiser, J.L., Targeting NADPH oxidases for the treatment of cancer and inflammation. Cell. Mol. Life Sci.: CMLS 69:14 (2012), 2435–2442.
41. [41] Weyemi, U., Redon, C.E., Parekh, P.R., Dupuy, C., Bonner, W.M., NADPH Oxidases NOXs and DUOXs as putative targets for cancer therapy. Anti-Cancer Agents Med. Chem. 13:3 (2013), 502–514.
42. [42] Diaz, B., Shani, G., Pass, I., Anderson, D., Quintavalle, M., Courtneidge, S.A., Tks5-dependent, nox-mediated generation of reactive oxygen species is necessary for invadopodia formation. Sci. Signal., 2(88), 2009, ra53.
43. [43] Shinohara, M., Shang, W.H., Kubodera, M., Harada, S., Mitsushita, J., Kato, M., Miyazaki, H., Sumimoto, H., Kamata, T., Nox1 redox signaling mediates oncogenic Ras-induced disruption of stress fibers and focal adhesions by down-regulating Rho. J. Biol. Chem. 282:24 (2007), 17640–17648.
44. [44] Dikalov, S., Cross talk between mitochondria and NADPH oxidases. Free Radic. Biol. Med. 51:7 (2011), 1289–1301.
45. [45] Shafique, E., Torina, A., Reichert, K., Colantuono, B., Nur, N., Zeeshan, K., Ravichandran, V., Liu, Y., Feng, J., Zeeshan, K., Benjamin, L.E., Irani, K., Harrington, E.O., Sellke, F.W., Abid, M.R., Mitochondrial redox plays a critical role in the paradoxical effects of NAPDH oxidase-derived ROS on coronary endothelium. Cardiovasc. Res. 113:2 (2017), 234–246.
46. [46] Meitzler, J.L., Antony, S., Wu, Y., Juhasz, A., Liu, H., Jiang, G., Lu, J., Roy, K., Doroshow, J.H., NADPH oxidases: a perspective on reactive oxygen species production in tumor biology. Antioxid. Redox Signal. 20:17 (2014), 2873–2889.
47. [47] Hayes, P., Knaus, U.G., Balancing reactive oxygen species in the epigenome: nadph oxidases as target and perpetrator. Antioxid. Redox Signal. 18:15 (2013), 1937–1945.
48. [48] Flores, M.V., Crawford, K.C., Pullin, L.M., Hall, C.J., Crosier, K.E., Crosier, P.S., Dual oxidase in the intestinal epithelium of zebrafish larvae has anti-bacterial properties. Biochem. Biophys. Res. Commun. 400:1 (2010), 164–168.
49. [49] Geiszt, M., Witta, J., Baffi, J., Lekstrom, K., Leto, T.L., Dual oxidases represent novel hydrogen peroxide sources supporting mucosal surface host defense. FASEB J.: Off. Publ. Fed. Am. Soc. Exp. Biol. 17:11 (2003), 1502–1504.
50. [50] Carvalho, D.P., Dupuy, C., Thyroid hormone biosynthesis and release. Mol. Cell. Endocrinol., 2017.
51. [51] Eskalli, Z., Achouri, Y., Hahn, S., Many, M.C., Craps, J., Refetoff, S., Liao, X.H., Dumont, J.E., Van Sande, J., Corvilain, B., Miot, F., De Deken, X., Overexpression of interleukin-4 in the thyroid of transgenic mice upregulates the expression of Duox1 and the anion transporter pendrin. Thyroid.: Off. J. Am. Thyroid. Assoc. 26:10 (2016), 1499–1512.
52. [52](a) Luxen, S., Belinsky, S.A., Knaus, U.G., Silencing of DUOX NADPH oxidases by promoter hypermethylation in lung cancer. Cancer Res. 68:4 (2008), 1037–1045.
53. [52](b) Cheadle, C., Vawter, M.P., Freed, W.J., Becker, K.G., Analysis of Microarray Data Using Z Score Transformation. J. Mol. Diagn. 5:2 (2003), 73–81.
54. [53] Chen, S.S., Yu, K.K., Ling, Q.X., Huang, C., Li, N., Zheng, J.M., Bao, S.X., Cheng, Q., Zhu, M.Q., Chen, M.Q., The combination of three molecular markers can be a valuable predictive tool for the prognosis of hepatocellular carcinoma patients. Sci. Rep., 6, 2016, 24582.
55. [54] Little, A.C., Sham, D., Hristova, M., Danyal, K., Heppner, D.E., Bauer, R.A., Sipsey, L.M., Habibovic, A., van der Vliet, A., DUOX1 silencing in lung cancer promotes EMT, cancer stem cell characteristics and invasive properties. Oncogenesis, 5, 2016, e261.
56. [55] Vignais, P.V., The superoxide-generating NADPH oxidase: structural aspects and activation mechanism. Cell. Mol. Life Sci. CMLS 59:9 (2002), 1428–1459.
57. [56] Bedard, K., Krause, K.H., The NOX family of ROS-generating NADPH oxidases: physiology and pathophysiology. Physiol. Rev. 87:1 (2007), 245–313.
58. [57] Brandes, R.P., Weissmann, N., Schroder, K., Nox family NADPH oxidases: molecular mechanisms of activation. Free Radic. Biol. Med. 76 (2014), 208–226.
59. [58] Leto, T.L., Geiszt, M., Role of Nox family NADPH oxidases in host defense. Antioxid. Redox Signal. 8:9–10 (2006), 1549–1561.
60. [59] Peshavariya, H., Dusting, G.J., Jiang, F., Halmos, L.R., Sobey, C.G., Drummond, G.R., Selemidis, S., NADPH oxidase isoform selective regulation of endothelial cell proliferation and survival. Naunyn-Schmiede.'s Arch. Pharmacol. 380:2 (2009), 193–204.
61. [60] Naughton, R., Quiney, C., Turner, S.D., Cotter, T.G., Bcr-Abl-mediated redox regulation of the PI3K/AKT pathway. Leukemia 23:8 (2009), 1432–1440.
62. [61] Reddy, M.M., Fernandes, M.S., Salgia, R., Levine, R.L., Griffin, J.D., Sattler, M., NADPH oxidases regulate cell growth and migration in myeloid cells transformed by oncogenic tyrosine kinases. Leukemia 25:2 (2011), 281–289.
63. [62] Jeong, H.Y., Jeong, H.Y., Kim, C.D., p22phox-Derived superoxide mediates enhanced proliferative capacity of diabetic vascular smooth muscle cells. Diabetes Res. Clin. Pract. 64:1 (2004), 1–10.
64. [63] Sardina, J.L., Lopez-Ruano, G., Sanchez-Abarca, L.I., Perez-Simon, J.A., Gaztelumendi, A., Trigueros, C., Llanillo, M., Sanchez-Yague, J., Hernandez-Hernandez, A., p22phox-Dependent NADPH oxidase activity is required for megakaryocytic differentiation. Cell Death Differ. 17:12 (2010), 1842–1854.
65. [64] Suh, Y.A., Arnold, R.S., Lassegue, B., Shi, J., Xu, X., Sorescu, D., Chung, A.B., Griendling, K.K., Lambeth, J.D., Cell transformation by the superoxide-generating oxidase Mox1. Nature 401:6748 (1999), 79–82.
66. [65] Laurent, E., McCoy, J.W. 3rd, Macina, R.A., Liu, W., Cheng, G., Robine, S., Papkoff, J., Lambeth, J.D., Nox1 is over-expressed in human colon cancers and correlates with activating mutations in K-Ras. Int. J. Cancer 123:1 (2008), 100–107.
67. [66] Banskota, S., Regmi, S.C., Kim, J.A., NOX1 to NOX2 switch deactivates AMPK and induces invasive phenotype in colon cancer cells through overexpression of MMP-7. Mol. Cancer, 14, 2015, 123.
68. [67] Raad, H., Serrano-Sanchez, M., Harfouche, G., Mahfouf, W., Bortolotto, D., Bergeron, V., Kasraian, Z., Dousset, L., Hosseini, M., Taieb, A., Rezvani, H.R., NADPH oxidase-1 plays a key role in keratinocyte responses to ultraviolet radiation and UVB-induced skin carcinogenesis. J. Invest. Dermatol., 2017.
69. [68] Zibara, K., Zeidan, A., Bjeije, H., Kassem, N., Badran, B., El-Zein, N., ROS mediates interferon gamma induced phosphorylation of Src, through the Raf/ERK pathway, in MCF-7 human breast cancer cell line. J. Cell Commun. Signal., 2016.
70. [69] Ito, K., Ota, A., Ono, T., Nakaoka, T., Wahiduzzaman, M., Karnan, S., Konishi, H., Furuhashi, A., Hayashi, T., Yamada, Y., Hosokawa, Y., Kazaoka, Y., Inhibition of Nox1 induces apoptosis by attenuating the AKT signaling pathway in oral squamous cell carcinoma cell lines. Oncol. Rep. 36:5 (2016), 2991–2998.
71. [70] Han, M., Zhang, T., Yang, L., Wang, Z., Ruan, J., Chang, X., Association between NADPH oxidase (NOX) and lung cancer: a systematic review and meta-analysis. J. Thorac. Dis. 8:7 (2016), 1704–1711.
72. [71] Xia, C., Meng, Q., Liu, L.Z., Rojanasakul, Y., Wang, X.R., Jiang, B.H., Reactive oxygen species regulate angiogenesis and tumor growth through vascular endothelial growth factor. Cancer Res. 67:22 (2007), 10823–10830.
73. [72] Boudreau, H.E., Casterline, B.W., Burke, D.J., Leto, T.L., Wild-type and mutant p53 differentially regulate NADPH oxidase 4 in TGF-beta-mediated migration of human lung and breast epithelial cells. Br. J. Cancer 110:10 (2014), 2569–2582.
74. [73] Ju, H.Q., Ying, H., Tian, T., Ling, J., Fu, J., Lu, Y., Wu, M., Yang, L., Achreja, A., Chen, G., Zhuang, Z., Wang, H., Nagrath, D., Yao, J., Hung, M.C., DePinho, R.A., Huang, P., Xu, R.H., Chiao, P.J., Mutant Kras- and p16-regulated NOX4 activation overcomes metabolic checkpoints in development of pancreatic ductal adenocarcinoma. Nat. Commun., 8, 2017, 14437.
75. [74] Lin, X.L., Yang, L., Fu, S.W., Lin, W.F., Gao, Y.J., Chen, H.Y., Ge, Z.Z., Overexpression of NOX4 predicts poor prognosis and promotes tumor progression in human colorectal cancer. Oncotarget, 2017.
76. [75] Holl, M., Koziel, R., Schafer, G., Pircher, H., Pauck, A., Hermann, M., Klocker, H., Jansen-Durr, P., Sampson, N., ROS signaling by NADPH oxidase 5 modulates the proliferation and survival of prostate carcinoma cells. Mol. Carcinog. 55:1 (2016), 27–39.
77. [76] Brar, S.S., Corbin, Z., Kennedy, T.P., Hemendinger, R., Thornton, L., Bommarius, B., Arnold, R.S., Whorton, A.R., Sturrock, A.B., Huecksteadt, T.P., Quinn, M.T., Krenitsky, K., Ardie, K.G., Lambeth, J.D., Hoidal, J.R., NOX5 NAD(P)H oxidase regulates growth and apoptosis in DU 145 prostate cancer cells, American journal of physiology. Cell Physiol. 285:2 (2003), C353–C369.
78. [77] Kamiguti, A.S., Serrander, L., Lin, K., Harris, R.J., Cawley, J.C., Allsup, D.J., Slupsky, J.R., Krause, K.H., Zuzel, M., Expression and activity of NOX5 in the circulating malignant B cells of hairy cell leukemia. J. Immunol. 175:12 (2005), 8424–8430 (1950).
79. [78] Fu, X., Beer, D.G., Behar, J., Wands, J., Lambeth, D., Cao, W., cAMP-response element-binding protein mediates acid-induced NADPH oxidase NOX5-S expression in Barrett esophageal adenocarcinoma cells. J. Biol. Chem. 281:29 (2006), 20368–20382.
80. [79] Carnesecchi, S., Rougemont, A.L., Doroshow, J.H., Nagy, M., Mouche, S., Gumy-Pause, F., Szanto, I., The NADPH oxidase NOX5 protects against apoptosis in ALK-positive anaplastic large-cell lymphoma cell lines. Free Radic. Biol. Med. 84 (2015), 22–29.
81. [80] Antony, S., Wu, Y., Hewitt, S.M., Anver, M.R., Butcher, D., Jiang, G., Meitzler, J.L., Liu, H., Juhasz, A., Lu, J., Roy, K.K., Doroshow, J.H., Characterization of NADPH oxidase 5 expression in human tumors and tumor cell lines with a novel mouse monoclonal antibody. Free Radic. Biol. Med. 65 (2013), 497–508.
82. [81] Dho, S.H., Kim, J.Y., Kwon, E.-S., Lim, J.C., Park, S.S., Kwon, K.-S., NOX5-L can stimulate proliferation and apoptosis depending on its levels and cellular context, determining cancer cell susceptibility to cisplatin. Oncotarget 6:36 (2015), 39235–39246.
83. [82] Mukawera, E., Chartier, S., Williams, V., Pagano, P.J., Lapointe, R., Grandvaux, N., Redox-modulating agents target NOX2-dependent IKKepsilon oncogenic kinase expression and proliferation in human breast cancer cell lines. Redox Biol. 6 (2015), 9–18.
84. [83] Aurelius, J., Hallner, A., Werlenius, O., Riise, R., Mollgard, L., Brune, M., Hansson, M., Martner, A., Thoren, F.B., Hellstrand, K., NOX2-dependent immunosuppression in chronic myelomonocytic leukemia. J. Leukoc. Biol., 2017.
85. [84] Guo, Y., Han, B., Luo, K., Ren, Z., Cai, L., Sun, L., NOX2-ROS-HIF-1alpha signaling is critical for the inhibitory effect of oleanolic acid on rectal cancer cell proliferation. Biomed. Pharmacother. 85 (2017), 733–739.
86. [85] Deep, G., Kumar, R., Jain, A.K., Dhar, D., Panigrahi, G.K., Hussain, A., Agarwal, C., El-Elimat, T., Sica, V.P., Oberlies, N.H., Agarwal, R., Graviola inhibits hypoxia-induced NADPH oxidase activity in prostate cancer cells reducing their proliferation and clonogenicity. Sci. Rep., 6, 2016, 23135.
87. [86] Wang, P., Shi, Q., Deng, W.H., Yu, J., Zuo, T., Mei, F.C., Wang, W.X., Relationship between expression of NADPH oxidase 2 and invasion and prognosis of human gastric cancer. World J. Gastroenterol. 21:20 (2015), 6271–6279.
88. [87] Mukherjea, D., Jajoo, S., Kaur, T., Sheehan, K.E., Ramkumar, V., Rybak, L.P., Transtympanic administration of short interfering (si)RNA for the NOX3 isoform of NADPH oxidase protects against cisplatin-induced hearing loss in the rat. Antioxid. Redox Signal. 13:5 (2010), 589–598.
89. [88] Helmcke, I., Heumuller, S., Tikkanen, R., Schroder, K., Brandes, R.P., Identification of structural elements in Nox1 and Nox4 controlling localization and activity. Antioxid. Redox Signal. 11:6 (2009), 1279–1287.
90. [89] Hilenski, L.L., Clempus, R.E., Quinn, M.T., Lambeth, J.D., Griendling, K.K., Distinct subcellular localizations of Nox1 and Nox4 in vascular smooth muscle cells. Arterioscler. Thromb. Vasc. Biol. 24:4 (2004), 677–683.
91. [90] Díaz, B., Courtneidge, S.A., Redox signaling at invasive microdomains in cancer cells. Free Radic. Biol. Med. 52:2 (2012), 247–256.
92. [91] Diaz, B., Shani, G., Pass, I., Anderson, D., Quintavalle, M., Courtneidge, S.A., Tks5-dependent, nox-mediated generation of reactive oxygen species is necessary for invadopodia formation. Sci. Signal., 2(88), 2009, ra53.
93. [92] Ushio-Fukai, M., Localizing NADPH oxidase–derived ROS. Sci.'s STKE, 2006(349), 2006, re8.
94. [93] Kawahara, T., Lambeth, J.D., Phosphatidylinositol (4,5)-bisphosphate modulates Nox5 localization via an n-terminal polybasic region. Mol. Biol. Cell 19:10 (2008), 4020–4031.
95. [94] Serrander, L., Jaquet, V., Bedard, K., Plastre, O., Hartley, O., Arnaudeau, S., Demaurex, N., Schlegel, W., Krause, K.H., NOX5 is expressed at the plasma membrane and generates superoxide in response to protein kinase C activation. Biochimie 89:9 (2007), 1159–1167.
96. [95] Donko, A., Peterfi, Z., Sum, A., Leto, T., Geiszt, M., Dual oxidases. Philos. Trans. R. Soc. Lond. Ser. B Biol. Sci. 360:1464 (2005), 2301–2308.
97. [96] Mumbengegwi, D.R., Li, Q., Li, C., Bear, C.E., Engelhardt, J.F., Evidence for a superoxide permeability pathway in endosomal membranes. Mol. Cell. Biol. 28:11 (2008), 3700–3712.
98. [97] Oakley, F.D., Abbott, D., Li, Q., Engelhardt, J.F., Signaling components of redox active endosomes: the redoxosomes. Antioxid. Redox Signal. 11:6 (2009), 1313–1333.
99. [98] Spencer, N.Y., Engelhardt, J.F., The basic biology of redoxosomes in cytokine-mediated signal transduction and implications for disease-specific therapies. Biochemistry 53:10 (2014), 1551–1564.
100. [99] Ushio-Fukai, M., Compartmentalization of redox signaling through NADPH oxidase-derived ROS. Antioxid. Redox Signal. 11:6 (2009), 1289–1299.
101. [100] Chen, K., Kirber, M.T., Xiao, H., Yang, Y., Keaney, J.F. Jr., Regulation of ROS signal transduction by NADPH oxidase 4 localization. J. Cell Biol. 181:7 (2008), 1129–1139.
102. [101] Block, K., Gorin, Y., Abboud, H.E., Subcellular localization of Nox4 and regulation in diabetes. Proc. Natl. Acad. Sci. USA 106:34 (2009), 14385–14390.
103. [102] Graham, K.A., Kulawiec, M., Owens, K.M., Li, X., Desouki, M.M., Chandra, D., Singh, K.K., NADPH oxidase 4 is an oncoprotein localized to mitochondria. Cancer Biol. Ther. 10:3 (2010), 223–231.
104. [103] Spencer, N.Y., Yan, Z., Boudreau, R.L., Zhang, Y., Luo, M., Li, Q., Tian, X., Shah, A.M., Davisson, R.L., Davidson, B., Banfi, B., Engelhardt, J.F., Control of hepatic nuclear superoxide production by glucose 6-phosphate dehydrogenase and NADPH oxidase-4. J. Biol. Chem. 286:11 (2011), 8977–8987.
105. [104] Weyemi, U., Lagente-Chevallier, O., Boufraqech, M., Prenois, F., Courtin, F., Caillou, B., Talbot, M., Dardalhon, M., Al Ghuzlan, A., Bidart, J.M., Schlumberger, M., Dupuy, C., ROS-generating NADPH oxidase NOX4 is a critical mediator in oncogenic H-Ras-induced DNA damage and subsequent senescence. Oncogene 31:9 (2012), 1117–1129.
106. [105] Qi, R., Zhou, Y., Li, X., Guo, H., Gao, L., Wu, L., Wang, Y., Gao, Q., DUOX2 expression is increased in barrett esophagus and cancerous tissues of stomach and colon. Gastroenterol. Res. Pract., 2016, 2016, 1835684.
107. [106] Wang, R., Dashwood, W.-M., Nian, H., Löhr, C.V., Fischer, K.A., Tsuchiya, N., Nakagama, H., Ashktorab, H., Dashwood, R.H., NADPH oxidase overexpression in human colon cancers and rat colon tumors induced by 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP). Int. J. Cancer 128:11 (2011), 2581–2590.
108. [107] Wu, Y., Meitzler, J.L., Antony, S., Juhasz, A., Lu, J., Jiang, G., Liu, H., Hollingshead, M., Haines, D.C., Butcher, D., Panter, M.S., Roy, K., Doroshow, J.H., Dual oxidase2 and pancreatic adenocarcinoma: IFN-gamma-mediated dual oxidase2 overexpression results in H2O2-induced, ERK associated up-regulation of HIF-1alpha and VEGF-A. Oncotarget 7:42 (2016), 68412–68433.
109. [108] Wu, Y., Lu, J., Antony, S., Juhasz, A., Liu, H., Jiang, G., Meitzler, J.L., Hollingshead, M., Haines, D.C., Butcher, D., Roy, K., Doroshow, J.H., Activation of TLR4 is required for the synergistic induction of dual oxidase 2 and dual oxidase A2 by IFN-gamma and lipopolysaccharide in human pancreatic cancer cell lines. J. Immunol. 190:4 (2013), 1859–1872 (1950).
110. [109] Wu, Y., Antony, S., Hewitt, S.M., Jiang, G., Yang, S.X., Meitzler, J.L., Juhasz, A., Lu, J., Liu, H., Doroshow, J.H., Roy, K., Functional activity and tumor-specific expression of dual oxidase 2 in pancreatic cancer cells and human malignancies characterized with a novel monoclonal antibody. Int. J. Oncol. 42:4 (2013), 1229–1238.
111. [110] Abdul Aziz, N.A., Mokhtar, N.M., Harun, R., Mollah, M.M., Mohamed Rose, I., Sagap, I., Mohd Tamil, A., Wan Ngah, W.Z., Jamal, R., A 19-gene expression signature as a predictor of survival in colorectal cancer. BMC Med. Genom., 9(1), 2016, 58.
112. [111] Ling, Q., Shi, W., Huang, C., Zheng, J., Cheng, Q., Yu, K., Chen, S., Zhang, H., Li, N., Chen, M., Epigenetic silencing of dual oxidase 1 by promoter hypermethylation in human hepatocellular carcinoma. Am. J. Cancer Res. 4:5 (2014), 508–517.
113. [112] Ameziane-El-Hassani, R., Talbot, M., de Souza Dos Santos, M.C., Al Ghuzlan, A., Hartl, D., Bidart, J.M., De Deken, X., Miot, F., Diallo, I., de Vathaire, F., Schlumberger, M., Dupuy, C., NADPH oxidase DUOX1 promotes long-term persistence of oxidative stress after an exposure to irradiation. Proc. Natl. Acad. Sci. USA 112:16 (2015), 5051–5056.
114. [113] Ameziane-El-Hassani, R., Schlumberger, M., Dupuy, C., NADPH oxidases: new actors in thyroid cancer?. Nat. Rev. Endocrinol. 12:8 (2016), 485–494.
115. [114] Damiano, S., Fusco, R., Morano, A., De Mizio, M., Paterno, R., De Rosa, A., Spinelli, R., Amente, S., Frunzio, R., Mondola, P., Miot, F., Laccetti, P., Santillo, M., Avvedimento, E.V., Reactive oxygen species regulate the levels of dual oxidase (Duox1-2) in human neuroblastoma cells. PLoS One, 7(4), 2012, e34405.
116. [115] Juhasz, A., Ge, Y., Markel, S., Chiu, A., Matsumoto, L., van Balgooy, J., Roy, K., Doroshow, J.H., Expression of NADPH oxidase homologues and accessory genes in human cancer cell lines, tumours and adjacent normal tissues. Free Radic. Res. 43:6 (2009), 523–532.
117. [116] De Deken, X., Corvilain, B., Dumont, J.E., Miot, F., Roles of DUOX-mediated hydrogen peroxide in metabolism, host defense, and signaling. Antioxid. Redox Signal. 20:17 (2014), 2776–2793.
118. [117] Pacquelet, S., Lehmann, M., Luxen, S., Regazzoni, K., Frausto, M., Noack, D., Knaus, U.G., Inhibitory action of NoxA1 on dual oxidase activity in airway cells. J. Biol. Chem. 283:36 (2008), 24649–24658.
119. [118] Carre, A., Louzada, R.A., Fortunato, R.S., Ameziane-El-Hassani, R., Morand, S., Ogryzko, V., de Carvalho, D.P., Grasberger, H., Leto, T.L., Dupuy, C., When an intramolecular disulfide bridge governs the interaction of DUOX2 with its partner DUOXA2. Antioxid. Redox Signal. 23:9 (2015), 724–733.
120. [119] Ueyama, T., Sakuma, M., Ninoyu, Y., Hamada, T., Dupuy, C., Geiszt, M., Leto, T.L., Saito, N., The extracellular A-loop of dual oxidases affects the specificity of reactive oxygen species release. J. Biol. Chem. 290:10 (2015), 6495–6506.
121. [120] Grasberger, H., Refetoff, S., Identification of the maturation factor for dual oxidase. Evolution of an eukaryotic operon equivalent. J. Biol. Chem. 281:27 (2006), 18269–18272.
122. [121] Luxen, S., Noack, D., Frausto, M., Davanture, S., Torbett, B.E., Knaus, U.G., Heterodimerization controls localization of Duox-DuoxA NADPH oxidases in airway cells. J. Cell Sci. 122:Pt 8 (2009), 1238–1247.
123. [122] Dupuy, C., Ohayon, R., Valent, A., Noel-Hudson, M.S., Deme, D., A. virion, purification of a novel flavoprotein involved in the thyroid NADPH oxidase. Cloning of the porcine and human cdnas. J. Biol. Chem. 274:52 (1999), 37265–37269.
124. [123] De Deken, X., Wang, D., Many, M.C., Costagliola, S., Libert, F., Vassart, G., Dumont, J.E., Miot, F., Cloning of two human thyroid cDNAs encoding new members of the NADPH oxidase family. J. Biol. Chem. 275:30 (2000), 23227–23233.
125. [124] Geiszt, M., NADPH oxidases: new kids on the block. Cardiovasc. Res. 71:2 (2006), 289–299.
126. [125] Leto, T.L., Geiszt, M., Role of Nox family NADPH oxidases in host defense. Antioxid. Redox Signal. 8:9–10 (2006), 1549–1561.
127. [126] Choi, H., Park, J.Y., Kim, H.J., Noh, M., Ueyama, T., Bae, Y., Lee, T.R., Shin, D.W., Hydrogen peroxide generated by DUOX1 regulates the expression levels of specific differentiation markers in normal human keratinocytes. J. Dermatol. Sci. 74:1 (2014), 56–63.
128. [127] Corcionivoschi, N., Alvarez, L.A., Sharp, T.H., Strengert, M., Alemka, A., Mantell, J., Verkade, P., Knaus, U.G., Bourke, B., Mucosal reactive oxygen species decrease virulence by disrupting Campylobacter jejuni phosphotyrosine signaling. Cell Host Microbe 12:1 (2012), 47–59.
129. [128] Moskwa, P., Lorentzen, D., Excoffon, K.J., Zabner, J., McCray, P.B. Jr., Nauseef, W.M., Dupuy, C., Banfi, B., A novel host defense system of airways is defective in cystic fibrosis. Am. J. Respir. Crit. Care Med. 175:2 (2007), 174–183.
130. [129] Grandvaux, N., Mariani, M., Fink, K., Lung epithelial NOX/DUOX and respiratory virus infections. Clin. Sci. 128:6 (2015), 337–347 (1979).
131. [130] Harper, R.W., Xu, C., Eiserich, J.P., Chen, Y., Kao, C.Y., Thai, P., Setiadi, H., Wu, R., Differential regulation of dual NADPH oxidases/peroxidases, Duox1 and Duox2, by Th1 and Th2 cytokines in respiratory tract epithelium. FEBS Lett. 579:21 (2005), 4911–4917.
132. [131] Fink, K., Duval, A., Martel, A., Soucy-Faulkner, A., Grandvaux, N., Dual role of NOX2 in respiratory syncytial virus- and sendai virus-induced activation of NF-kappab in airway epithelial cells. J. Immunol. 180:10 (2008), 6911–6922 (1950).
133. [132] Fink, K., Martin, L., Mukawera, E., Chartier, S., De Deken, X., Brochiero, E., Miot, F., Grandvaux, N., IFN[beta]/TNF[alpha] synergism induces a non-canonical STAT2/IRF9-dependent pathway triggering a novel DUOX2 NADPH oxidase-mediated airway antiviral response. Cell Res. 23:5 (2013), 673–690.
134. [133] Gattas, M.V., Forteza, R., Fragoso, M.A., Fregien, N., Salas, P., Salathe, M., Conner, G.E., Oxidative epithelial host defense is regulated by infectious and inflammatory stimuli. Free Radic. Biol. Med. 47:10 (2009), 1450–1458.
135. [134] Sham, D., Wesley, U.V., Hristova, M., van der Vliet, A., ATP-mediated transactivation of the epidermal growth factor receptor in airway epithelial cells involves DUOX1-dependent oxidation of Src and ADAM17. PLoS One, 8(1), 2013, e54391.
136. [135] van der Vliet, A., Janssen-Heininger, Y.M.W., Hydrogen peroxide as a damage signal in tissue injury and inflammation: murderer, mediator, or messenger?. J. Cell. Biochem. 115:3 (2014), 427–435.
137. [136] Razzell, W., Evans, Iwan R., Martin, P., Wood, W., Calcium flashes orchestrate the wound inflammatory response through DUOX activation and hydrogen peroxide release. Curr. Biol. 23:5 (2013), 424–429.
138. [137] Cordeiro, J.V., Jacinto, A., The role of transcription-independent damage signals in the initiation of epithelial wound healing. Nat. Rev. Mol. Cell Biol. 14:4 (2013), 249–262.
139. [138] Cauwels, A., Rogge, E., Vandendriessche, B., Shiva, S., Brouckaert, P., Extracellular ATP drives systemic inflammation, tissue damage and mortality. Cell Death Dis., 5, 2014, e1102.
140. [139] Wesley, U.V., Bove, P.F., Hristova, M., McCarthy, S., van der Vliet, A., Airway epithelial cell migration and wound repair by ATP-mediated activation of dual oxidase 1. J. Biol. Chem. 282:5 (2007), 3213–3220.
141. [140] Gorissen, S.H., Hristova, M., Habibovic, A., Sipsey, L.M., Spiess, P.C., Janssen-Heininger, Y.M., van der Vliet, A., Dual oxidase-1 is required for airway epithelial cell migration and bronchiolar reepithelialization after injury. Am. J. Respir. Cell Mol. Biol. 48:3 (2013), 337–345.
142. [141] Hirakawa, S., Saito, R., Ohara, H., Okuyama, R., Aiba, S., Dual oxidase 1 induced by Th2 cytokines promotes STAT6 phosphorylation via oxidative inactivation of protein tyrosine phosphatase 1B in human epidermal keratinocytes. J. Immunol. 186:8 (2011), 4762–4770 (1950).
143. [142] de Oliveira, S., Boudinot, P., Calado, A., Mulero, V., Duox1-derived H2O2 modulates Cxcl8 expression and neutrophil recruitment via JNK/c-JUN/AP-1 signaling and chromatin modifications. J. Immunol. 194:4 (2015), 1523–1533 (1950).
144. [143] Cho, D.Y., Nayak, J.V., Bravo, D.T., Le, W., Nguyen, A., Edward, J.A., Hwang, P.H., Illek, B., Fischer, H., Expression of dual oxidases and secreted cytokines in chronic rhinosinusitis. Int. Forum Allergy Rhinol. 3:5 (2013), 376–383.
145. [144] Hristova, M., Habibovic, A., Veith, C., Janssen-Heininger, Y.M., Dixon, A.E., Geiszt, M., van der Vliet, A., Airway epithelial dual oxidase 1 mediates allergen-induced IL-33 secretion and activation of type 2 immune responses. J. Allergy Clin. Immunol. 137:5 (2016), 1545–1556.e11.
146. [145] Chang, S., Linderholm, A., Franzi, L., Kenyon, N., Grasberger, H., Harper, R., Dual oxidase regulates neutrophil recruitment in allergic airways. Free Radic. Biol. Med. 65 (2013), 38–46.
147. [146] Habibovic, A., Hristova, M., Heppner, D.E., Danyal, K., Ather, J.L., Janssen-Heininger, Y.M., Irvin, C.G., Poynter, M.E., Lundblad, L.K., Dixon, A.E., Geiszt, M., van der Vliet, A., DUOX1 mediates persistent epithelial EGFR activation, mucous cell metaplasia, and airway remodeling during allergic asthma. JCI Insight, 1(18), 2016, e88811.
148. [147] Kwon, J., Shatynski, K.E., Chen, H., Morand, S., de Deken, X., Miot, F., Leto, T.L., Williams, M.S., The nonphagocytic NADPH oxidase Duox1 mediates a positive feedback loop during T cell receptor signaling. Sci. Signal., 3(133), 2010, ra59.
149. [148] Heppner, D.E., Hristova, M., Dustin, C.M., Danyal, K., Habibovic, A., van der Vliet, A., The NADPH oxidases DUOX1 and NOX2 play distinct roles in redox regulation of epidermal growth factor receptor signaling. J. Biol. Chem. 291:44 (2016), 23282–23293.
150. [149] Enyedi, B., Niethammer, P., H2O2: a chemoattractant?. Methods Enzymol. 528 (2013), 237–255.
151. [150] Niethammer, P., Grabher, C., Look, A.T., Mitchison, T.J., A tissue-scale gradient of hydrogen peroxide mediates rapid wound detection in zebrafish. Nature 459:7249 (2009), 996–999.
152. [151] Bedard, K., Lardy, B., Krause, K.-H., NOX family NADPH oxidases: not just in mammals. Biochimie 89:9 (2007), 1107–1112.
153. [152] Buchon, N., Broderick, N.A., Lemaitre, B., Gut homeostasis in a microbial world: insights from Drosophila melanogaster. Nat. Rev. Microbiol. 11:9 (2013), 615–626.
154. [153] Damante, G., Tell, G., Di Lauro, R., A unique combination of transcription factors controls differentiation of thyroid cells. Progress. Nucleic Acid. Res. Mol. Biol. 66 (2001), 307–356.
155. [154] Cardoso-Weide, L.C., Cardoso-Penha, R.C., Costa, M.W., Ferreira, A.C., Carvalho, D.P., Santisteban, P.S., DuOx2 promoter regulation by hormones, transcriptional factors and the coactivator TAZ. Eur. Thyroid J. 4:1 (2015), 6–13.
156. [155] Fischer, H., Gonzales, L.K., Kolla, V., Schwarzer, C., Miot, F., Illek, B., Ballard, P.L., Developmental regulation of DUOX1 expression and function in human fetal lung epithelial cells. Am. J. Physiol. Lung Cell. Mol. Physiol. 292:6 (2007), L1506–L1514.
157. [156] Linderholm, A.L., Onitsuka, J., Xu, C., Chiu, M., Lee, W.M., Harper, R.W., All-trans retinoic acid mediates DUOX2 expression and function in respiratory tract epithelium. Am. J. Physiol. Lung Cell. Mol. Physiol. 299:2 (2010), L215–L221.
158. [157] Xu, C., Linderholm, A., Grasberger, H., Harper, R.W., Dual oxidase 2 bidirectional promoter polymorphisms confer differential immune responses in airway epithelia. Am. J. Respir. Cell Mol. Biol. 47:4 (2012), 484–490.
159. [158] Grandvaux, N., Mariani, M., Fink, K., Lung epithelial NOX/DUOX and respiratory virus infections. Clin. Sci. 128:6 (2015), 337–347 (1979).
160. [159] Fischer, H., Mechanisms and function of DUOX in epithelia of the lung. Antioxid. Redox Signal. 11:10 (2009), 2453–2465.
161. [160] Wang, J., Shao, M., Liu, M., Peng, P., Li, L., Wu, W., Wang, L., Duan, F., Zhang, M., Song, S., Jia, D., Ruan, Y., Gu, J., PKCalpha promotes generation of reactive oxygen species via DUOX2 in hepatocellular carcinoma. Biochem Biophys. Res Commun. 463:4 (2015), 839–845.
162. [161] Wu, Y., Antony, S., Juhasz, A., Lu, J., Ge, Y., Jiang, G., Roy, K., Doroshow, J.H., Up-regulation and sustained activation of Stat1 Are essential for interferon-γ (IFN-γ)-induced dual oxidase 2 (Duox2) and dual oxidase A2 (DuoxA2) expression in human pancreatic cancer cell lines. J. Biol. Chem. 286:14 (2011), 12245–12256.
163. [162] Apte, R.N., Dotan, S., Elkabets, M., White, M.R., Reich, E., Carmi, Y., Song, X., Dvozkin, T., Krelin, Y., Voronov, E., The involvement of IL-1 in tumorigenesis, tumor invasiveness, metastasis and tumor-host interactions. Cancer Metastasis Rev. 25:3 (2006), 387–408.
164. [163] Lewis, A.M., Varghese, S., Xu, H., Alexander, H.R., Interleukin-1 and cancer progression: the emerging role of interleukin-1 receptor antagonist as a novel therapeutic agent in cancer treatment. J. Transl. Med., 4, 2006 (48-48).
165. [164] Li, Y., Wang, L., Pappan, L., Galliher-Beckley, A., Shi, J., IL-1β promotes stemness and invasiveness of colon cancer cells through Zeb1 activation. Mol. Cancer, 11(1), 2012, 87.
166. [165] Voronov, E., Carmi, Y., Apte, R., The role IL-1 in tumor-mediated angiogenesis. Front. Physiol., 5(114), 2014.
167. [166] Voronov, E., Shouval, D.S., Krelin, Y., Cagnano, E., Benharroch, D., Iwakura, Y., Dinarello, C.A., Apte, R.N., IL-1 is required for tumor invasiveness and angiogenesis. Proc. Natl. Acad. Sci. 100:5 (2003), 2645–2650.
168. [167] MacFie, T.S., Poulsom, R., Parker, A., Warnes, G., Boitsova, T., Nijhuis, A., Suraweera, N., Poehlmann, A., Szary, J., Feakins, R., Jeffery, R., Harper, R.W., Jubb, A.M., Lindsay, J.O., Silver, A., DUOX2 and DUOXA2 form the predominant enzyme system capable of producing the reactive oxygen species H2O2 in active ulcerative colitis and are modulated by 5-aminosalicylic acid. Inflamm. Bowel Dis. 20:3 (2014), 514–524.
169. [168] Hayes, P., Dhillon, S., O'Neill, K., Thoeni, C., Hui, K.Y., Elkadri, A., Guo, C.H., Kovacic, L., Aviello, G., Alvarez, L.A., Griffiths, A.M., Snapper, S.B., Brant, S.R., Doroshow, J.H., Silverberg, M.S., Peter, I., McGovern, D.P., Cho, J., Brumell, J.H., Uhlig, H.H., Bourke, B., Muise, A.A., Knaus, U.G., Defects in NADPH oxidase genes NOX1 and DUOX2 in very early onset inflammatory bowel disease. Cell. Mol. Gastroenterol. Hepatol. 1:5 (2015), 489–502.
170. [169] Joo, J.H., Ryu, J.H., Kim, C.H., Kim, H.J., Suh, M.S., Kim, J.O., Chung, S.Y., Lee, S.N., Kim, H.M., Bae, Y.S., Yoon, J.H., Dual oxidase 2 is essential for the toll-like receptor 5-mediated inflammatory response in airway mucosa. Antioxid. Redox Signal. 16:1 (2012), 57–70.
171. [170] Suzuki, A., Leland, P., Joshi, B.H., Puri, R.K., Targeting of IL-4 and IL-13 receptors for cancer therapy. Cytokine 75:1 (2015), 79–88.
172. [171] Paska, A.V., Hudler, P., Aberrant methylation patterns in cancer: a clinical view. Biochem. Med. 25:2 (2015), 161–176.
173. [172] Liu, F., Wang, L., Perna, F., Nimer, S.D., Beyond transcription factors: how oncogenic signalling reshapes the epigenetic landscape. Nat. Rev. Cancer 16:6 (2016), 359–372.
174. [173] Mark A. Dawson, T. Kouzarides, Cancer epigenetics: from mechanism to therapy, Cell 150 (1) (2012) 12–27.
175. [174] Feinberg, A.P., Koldobskiy, M.A., Gondor, A., Epigenetic modulators, modifiers and mediators in cancer aetiology and progression. Nat. Rev. Genet. 17:5 (2016), 284–299.
176. [175] S.B. Baylin, DNA methylation and gene silencing in cancer, Nat. Clin. Prac. Oncol.
177. [176] Jones, P.A., Baylin, S.B., The epigenomics of cancer. Cell 128:4 (2007), 683–692.
178. [177] Wu, B.K., Mei, S.C., Brenner, C., RFTS-deleted DNMT1 enhances tumorigenicity with focal hypermethylation and global hypomethylation. Cell Cycle 13:20 (2014), 3222–3231.
179. [178] Li, L., He, S., Sun, J.M., Davie, J.R., Gene regulation by Sp1 and Sp3. Biochem. Cell Biol. = Biochim. Biol. Cell. 82:4 (2004), 460–471.
180. [179] Zelko, I.N., Mueller, M.R., Folz, R.J., CpG methylation attenuates Sp1 and Sp3 binding to the human extracellular superoxide dismutase promoter and regulates its cell-specific expression. Free Radic. Biol. Med. 48:7 (2010), 895–904.
181. [180] Bai, G., Hock, T.D., Logsdon, N., Zhou, Y., Thannickal, V.J., A far-upstream AP-1/Smad binding box regulates human NOX4 promoter activation by transforming growth factor-beta. Gene 540:1 (2014), 62–67.
182. [181] Sanders, Y.Y., Liu, H., Liu, G., Thannickal, V.J., Epigenetic mechanisms regulate NADPH oxidase-4 expression in cellular senescence. Free Radic. Biol. Med. 79 (2015), 197–205.
183. [182] Chiappinelli, K.B., Zahnow, C.A., Ahuja, N., Baylin, S.B., Combining epigenetic and immunotherapy to combat cancer. Cancer Res. 76:7 (2016), 1683–1689.
184. [183] Liu, L., Chen, L., Wu, X., Li, X., Song, Y., Mei, Q., Nie, J., Han, W., Low-dose DNA-demethylating agent enhances the chemosensitivity of cancer cells by targeting cancer stem cells via the upregulation of microRNA-497. J. Cancer Res. Clin. Oncol. 142:7 (2016), 1431–1439.
185. [184] Qiu, Y.-Y., Mirkin, B.L., Dwivedi, R.S., Inhibition of DNA methyltransferase reverses cisplatin induced drug resistance in murine neuroblastoma cells. Cancer Detect. Prev. 29:5 (2005), 456–463.
186. [185] Soengas, M.S., Capodieci, P., Polsky, D., Mora, J., Esteller, M., Opitz-Araya, X., McCombie, R., Herman, J.G., Gerald, W.L., Lazebnik, Y.A., Cordon-Cardo, C., Lowe, S.W., Inactivation of the apoptosis effector Apaf-1 in malignant melanoma. Nature 409:6817 (2001), 207–211.
187. [186] Szyf, M., The role of dna hypermethylation and demethylation in cancer and cancer therapy. Curr. Oncol. 15:2 (2008), 72–75.
188. [187] Che, M., Wang, R., Li, X., Wang, H.Y., Zheng, X.F., Expanding roles of superoxide dismutases in cell regulation and cancer. Drug Discov. Today 21:1 (2016), 143–149.
189. [188] Laukkanen, M.O., Extracellular superoxide dismutase: growth promoter or tumor suppressor?. Oxid. Med. Cell. Longev., 2016, 2016, 3612589.
190. [189] O'Leary, B.R., Fath, M.A., Bellizzi, A.M., Hrabe, J.E., Button, A.M., Allen, B.G., Case, A.J., Altekruse, S., Wagner, B.A., Buettner, G.R., Lynch, C.F., Hernandez, B.Y., Cozen, W., Beardsley, R.A., Keene, J., Henry, M.D., Domann, F.E., Spitz, D.R., Mezhir, J.J., Loss of SOD3 (EcSOD) expression promotes an aggressive phenotype in human pancreatic ductal adenocarcinoma. Clin. Cancer Res.: An Off. J. Am. Assoc. Cancer Res. 21:7 (2015), 1741–1751.
191. [190] Teoh-Fitzgerald, M.L., Fitzgerald, M.P., Zhong, W., Askeland, R.W., Domann, F.E., Epigenetic reprogramming governs EcSOD expression during human mammary epithelial cell differentiation, tumorigenesis and metastasis. Oncogene 33:3 (2014), 358–368.
192. [191] Teoh-Fitzgerald, M.L., Fitzgerald, M.P., Jensen, T.J., Futscher, B.W., Domann, F.E., Genetic and epigenetic inactivation of extracellular superoxide dismutase promotes an invasive phenotype in human lung cancer by disrupting ECM homeostasis. Mol. Cancer Res.: MCR 10:1 (2012), 40–51.
193. [192] Teoh, M.L., Fitzgerald, M.P., Oberley, L.W., Domann, F.E., Overexpression of extracellular superoxide dismutase attenuates heparanase expression and inhibits breast carcinoma cell growth and invasion. Cancer Res. 69:15 (2009), 6355–6363.
194. [193] Robertson, K.D., DNA methylation, methyltransferases, and cancer. Oncogene 20:24 (2001), 3139–3155.
195. [194] Esteve, P.O., Chang, Y., Samaranayake, M., Upadhyay, A.K., Horton, J.R., Feehery, G.R., Cheng, X., Pradhan, S., A methylation and phosphorylation switch between an adjacent lysine and serine determines human DNMT1 stability. Nat. Struct. Mol. Biol. 18:1 (2011), 42–48.
196. [195] Wu, Q., Ni, X., ROS-mediated, DNA methylation pattern alterations in carcinogenesis. Curr. Drug Targets 16:1 (2015), 13–19.
197. [196] Falkenberg, K.J., Johnstone, R.W., Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders. Nat. Rev. Drug Discov. 13:9 (2014), 673–691.
198. [197] Tahiliani, M., Koh, K.P., Shen, Y., Pastor, W.A., Bandukwala, H., Brudno, Y., Agarwal, S., Iyer, L.M., Liu, D.R., Aravind, L., Rao, A., Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1. Science 324:5929 (2009), 930–935.
199. [198] Kohli, R.M., Zhang, Y., TET enzymes, TDG and the dynamics of DNA demethylation. Nature 502:7472 (2013), 472–479.
200. [199] Li, D., Guo, B., Wu, H., Tan, L., Lu, Q., TET family of dioxygenases: crucial roles and underlying mechanisms. Cytogenet. Genome Res. 146:3 (2015), 171–180.
201. [200] Wu, B.K., Brenner, C., Suppression of TET1-dependent DNA demethylation is essential for KRAS-mediated transformation. Cell Rep. 9:5 (2014), 1827–1840.
202. [201] Neri, F., Dettori, D., Incarnato, D., Krepelova, A., Rapelli, S., Maldotti, M., Parlato, C., Paliogiannis, P., Oliviero, S., TET1 is a tumour suppressor that inhibits colon cancer growth by derepressing inhibitors of the WNT pathway. Oncogene 34:32 (2015), 4168–4176.
203. [202] Forloni, M., Gupta, R., Nagarajan, A., Sun, L.S., Dong, Y., Pirazzoli, V., Toki, M., Wurtz, A., Melnick, M.A., Kobayashi, S., Homer, R.J., Rimm, D.L., Gettinger, S.J., Politi, K., Dogra, S.K., Wajapeyee, N., Oncogenic EGFR represses the TET1 DNA demethylase to induce silencing of tumor suppressors in cancer cells. Cell Rep. 16:2 (2016), 457–471.
204. [203] Li, L., Li, C., Mao, H., Du, Z., Chan, W.Y., Murray, P., Luo, B., Chan, A.T., Mok, T.S., Chan, F.K., Ambinder, R.F., Tao, Q., Epigenetic inactivation of the CpG demethylase TET1 as a DNA methylation feedback loop in human cancers. Sci. Rep., 6, 2016, 26591.
205. [204] Blaschke, K., Ebata, K.T., Karimi, M.M., Zepeda-Martinez, J.A., Goyal, P., Mahapatra, S., Tam, A., Laird, D.J., Hirst, M., Rao, A., Lorincz, M.C., Ramalho-Santos, M., Vitamin C induces Tet-dependent DNA demethylation and a blastocyst-like state in ES cells. Nature 500:7461 (2013), 222–226.
206. [205] Minor, E.A., Court, B.L., Young, J.I., Wang, G., Ascorbate induces ten-eleven translocation (Tet) methylcytosine dioxygenase-mediated generation of 5-hydroxymethylcytosine. J. Biol. Chem. 288:19 (2013), 13669–13674.
207. [206] Nordgren, K.K., Skildum, A.J., The deep end of the metabolite pool: influences on epigenetic regulatory mechanisms in cancer. Eur. J. Clin. Invest. 45:Suppl. 1 (2015), S9–S15.
208. [207] Sciacovelli, M., Frezza, C., Oncometabolites: unconventional triggers of oncogenic signalling cascades. Free Radic. Biol. Med. 100 (2016), 175–181.
209. [208] Nitta, T., Mitsuhashi, T., Hatanaka, Y., Miyamoto, M., Oba, K., Tsuchikawa, T., Suzuki, Y., Hatanaka, K.C., Hirano, S., Matsuno, Y., Prognostic significance of epithelial-mesenchymal transition-related markers in extrahepatic cholangiocarcinoma: comprehensive immunohistochemical study using a tissue microarray. Br. J. Cancer 111:7 (2014), 1363–1372.
210. [209] Heerboth, S., Housman, G., Leary, M., Longacre, M., Byler, S., Lapinska, K., Willbanks, A., Sarkar, S., EMT and tumor metastasis. Clin. Transl. Med., 4, 2015, 6.
211. [210] Singh, A., Settleman, J., EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene 29:34 (2010), 4741–4751.
212. [211] Hristova, M., Habibovic, A., Veith, C., Janssen-Heininger, Y.M., Dixon, A.E., Geiszt, M., van der Vliet, A., Airway epithelial dual oxidase 1 mediates allergen-induced IL-33 secretion and activation of type 2 immune responses. J. Allergy Clin. Immunol. 137:5 (2016), 1545–1556 (e11).
213. [212] Lemmon, M.A., Schlessinger, J., Ferguson, K.M., The EGFR family: not so prototypical receptor tyrosine kinases. Cold Spring Harb. Perspect. Biol., 6(4), 2014, a020768.
214. [213] Borg, J.P., Marchetto, S., Le Bivic, A., Ollendorff, V., Jaulin-Bastard, F., Saito, H., Fournier, E., Adelaide, J., Margolis, B., Birnbaum, D., ERBIN: a basolateral PDZ protein that interacts with the mammalian ERBB2/HER2 receptor. Nat. Cell Biol. 2:7 (2000), 407–414.
215. [214] He, C., Hobert, M., Friend, L., Carlin, C., The epidermal growth factor receptor juxtamembrane domain has multiple basolateral plasma membrane localization determinants, including a dominant signal with a polyproline core. J. Biol. Chem. 277:41 (2002), 38284–38293.
216. [215] Singh, B., Coffey, R.J., Trafficking of epidermal growth factor receptor ligands in polarized epithelial cells. Annu. Rev. Physiol. 76 (2014), 275–300.
217. [216] Vermeer, P.D., Einwalter, L.A., Moninger, T.O., Rokhlina, T., Kern, J.A., Zabner, J., Welsh, M.J., Segregation of receptor and ligand regulates activation of epithelial growth factor receptor. Nature 422:6929 (2003), 322–326.
218. [217] Qian, X., Karpova, T., Sheppard, A.M., McNally, J., Lowy, D.R., E-cadherin-mediated adhesion inhibits ligand-dependent activation of diverse receptor tyrosine kinases. EMBO J. 23:8 (2004), 1739–1748.
219. [218] Su, B., Gao, L., Meng, F., Guo, L.W., Rothschild, J., Gelman, I.H., Adhesion-mediated cytoskeletal remodeling is controlled by the direct scaffolding of Src from FAK complexes to lipid rafts by SSeCKS/AKAP12. Oncogene 32:16 (2013), 2016–2026.
220. [219] Citri, A., Yarden, Y., EGF–ERBB signalling: towards the systems level. Nat. Rev. Mol. Cell Biol. 7:7 (2006), 505–516.
221. [220] Yarden, Y., Pines, G., The ERBB network: at last, cancer therapy meets systems biology. Nat. Rev. Cancer 12:8 (2012), 553–563.
222. [221] Singh, A., Settleman, J., EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene 29:34 (2010), 4741–4751.
223. [222] Yewale, C., Baradia, D., Vhora, I., Patil, S., Misra, A., Epidermal growth factor receptor targeting in cancer: a review of trends and strategies. Biomaterials 34:34 (2013), 8690–8707.
224. [223] Herbst, R.S., Shin, D.M., Monoclonal antibodies to target epidermal growth factor receptor-positive tumors: a new paradigm for cancer therapy. Cancer 94:5 (2002), 1593–1611.
225. [224] Chong, C.R., Janne, P.A., The quest to overcome resistance to EGFR-targeted therapies in cancer. Nat. Med. 19:11 (2013), 1389–1400.
226. [225] X. Tan, P.F. Lambert, A.C. Rapraeger, R.A. Anderson, Stress-induced EGFR trafficking: mechanisms, functions, and therapeutic implications, Trends Cell Biol. 26 (5) (2016) 352–366.
227. [226] A. Tomas, C.E. Futter, E.R. Eden, EGF receptor trafficking: consequences for signaling and cancer, Trends Cell Biol. 24 (1) (2014) 26–34.
228. [227] Brand, T.M., Iida, M., Li, C., Wheeler, D.L., The nuclear epidermal growth factor receptor signaling network and its role in cancer. Discov. Med. 12:66 (2011), 419–432.
229. [228] Brand, T.M., Iida, M., Luthar, N., Starr, M.M., Huppert, E.J., Wheeler, D.L., Nuclear EGFR as a molecular target in cancer. Radiother. Oncol.: J. Eur. Soc. Ther. Radiol. Oncol. 108:3 (2013), 370–377.
230. [229] Che, T.F., Lin, C.W., Wu, Y.Y., Chen, Y.J., Han, C.L., Chang, Y.L., Wu, C.T., Hsiao, T.H., Hong, T.M., Yang, P.C., Mitochondrial translocation of EGFR regulates mitochondria dynamics and promotes metastasis in NSCLC. Oncotarget 6:35 (2015), 37349–37366.
231. [230] Thomson, S., Buck, E., Petti, F., Griffin, G., Brown, E., Ramnarine, N., Iwata, K.K., Gibson, N., Haley, J.D., Epithelial to mesenchymal transition is a determinant of sensitivity of non-small-cell lung carcinoma cell lines and xenografts to epidermal growth factor receptor inhibition. Cancer Res. 65:20 (2005), 9455–9462.
232. [231] Ren, S., Su, C., Wang, Z., Li, J., Fan, L., Li, B., Li, X., Zhao, C., Wu, C., Hou, L., He, Y., Gao, G., Chen, X., Ren, J., Li, A., Xu, G., Zhou, X., Zhou, C., Schmid-Bindert, G., Epithelial phenotype as a predictive marker for response to EGFR-TKIs in non-small cell lung cancer patients with wild-type EGFR. Int. J. Cancer 135:12 (2014), 2962–2971.
233. [232] Thomson, S., Petti, F., Sujka-Kwok, I., Epstein, D., Haley, J.D., Kinase switching in mesenchymal-like non-small cell lung cancer lines contributes to EGFR inhibitor resistance through pathway redundancy. Clin. Exp. Metastasis 25:8 (2008), 843–854.
234. [233] Wheeler, D.L., Iida, M., Kruser, T.J., Nechrebecki, M.M., Dunn, E.F., Armstrong, E.A., Huang, S., Harari, P.M., Epidermal growth factor receptor cooperates with Src family kinases in acquired resistance to cetuximab. Cancer Biol. Ther. 8:8 (2009), 696–703.
235. [234] Mitsudomi, T., Yatabe, Y., Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer. Cancer Sci. 98:12 (2007), 1817–1824.
236. [235] Giannoni, E., Parri, M., Chiarugi, P., EMT and oxidative stress: a bidirectional interplay affecting tumor malignancy. Antioxid. Redox Signal. 16:11 (2012), 1248–1263.
237. [236] Paulsen, C.E., Truong, T.H., Garcia, F.J., Homann, A., Gupta, V., Leonard, S.E., Carroll, K.S., Peroxide-dependent sulfenylation of the EGFR catalytic site enhances kinase activity. Nat. Chem. Biol. 8:1 (2012), 57–64.
238. [237] Truong, T.H., Carroll, K.S., Redox regulation of epidermal growth factor receptor signaling through cysteine oxidation. Biochemistry 51:50 (2012), 9954–9965.
239. [238] Truong, T.H., Ung, P.M., Palde, P.B., Paulsen, C.E., Schlessinger, A., Carroll, K.S., Molecular basis for redox activation of epidermal growth factor receptor kinase. Cell Chem. Biol. 23:7 (2016), 837–848.
240. [239] Heppner, D.E., van der Vliet, A., Redox-dependent regulation of epidermal growth factor receptor signaling. Redox Biol. 8 (2016), 24–27.
241. [240] Schwartz, P.A., Kuzmic, P., Solowiej, J., Bergqvist, S., Bolanos, B., Almaden, C., Nagata, A., Ryan, K., Feng, J., Dalvie, D., Kath, J.C., Xu, M., Wani, R., Murray, B.W., Covalent EGFR inhibitor analysis reveals importance of reversible interactions to potency and mechanisms of drug resistance. Proc. Natl. Acad. Sci. USA 111:1 (2014), 173–178.
242. [241] Wani, R., Nagata, A., Murray, B.W., Protein redox chemistry: post-translational cysteine modifications that regulate signal transduction and drug pharmacology. Front. Pharmacol., 5(224), 2014.
243. [242] Heppner, D.E., Janssen-Heininger, Y.M., van der Vliet, A., The role of sulfenic acids in cellular redox signaling: reconciling chemical kinetics and molecular detection strategies. Arch. Biochem. Biophys. 616 (2017), 40–46.
244. [243] Sirokmany, G., Pato, A., Zana, M., Donko, A., Biro, A., Nagy, P., Geiszt, M., Epidermal growth factor-induced hydrogen peroxide production is mediated by dual oxidase 1. Free Radic. Biol. Med. 97 (2016), 204–211.
245. [244] Cross, D.A., Ashton, S.E., Ghiorghiu, S., Eberlein, C., Nebhan, C.A., Spitzler, P.J., Orme, J.P., Finlay, M.R., Ward, R.A., Mellor, M.J., Hughes, G., Rahi, A., Jacobs, V.N., Red Brewer, M., Ichihara, E., Sun, J., Jin, H., Ballard, P., Al-Kadhimi, K., Rowlinson, R., Klinowska, T., Richmond, G.H., Cantarini, M., Kim, D.W., Ranson, M.R., Pao, W., AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. Cancer Discov. 4:9 (2014), 1046–1061.
246. [245] Thress, K.S., Paweletz, C.P., Felip, E., Cho, B.C., Stetson, D., Dougherty, B., Lai, Z., Markovets, A., Vivancos, A., Kuang, Y., Ercan, D., Matthews, S.E., Cantarini, M., Barrett, J.C., Janne, P.A., Oxnard, G.R., Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M. Nat. Med. 21:6 (2015), 560–562.
247. [246] Jia, Y., Yun, C.H., Park, E., Ercan, D., Manuia, M., Juarez, J., Xu, C., Rhee, K., Chen, T., Zhang, H., Palakurthi, S., Jang, J., Lelais, G., DiDonato, M., Bursulaya, B., Michellys, P.Y., Epple, R., Marsilje, T.H., McNeill, M., Lu, W., Harris, J., Bender, S., Wong, K.K., Janne, P.A., Eck, M.J., Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors. Nature 534:7605 (2016), 129–132.
248. [247] Tan, X., Lambert, P.F., Rapraeger, A.C., Anderson, R.A., Stress-induced EGFR trafficking: mechanisms, functions, and therapeutic implications. Trends Cell Biol. 26:5 (2016), 352–366.
249. [248] Morand, S., Ueyama, T., Tsujibe, S., Saito, N., Korzeniowska, A., Leto, T.L., Duox maturation factors form cell surface complexes with Duox affecting the specificity of reactive oxygen species generation. FASEB J.: Off. Publ. Fed. Am. Soc. Exp. Biol. 23:4 (2009), 1205–1218.
250. [249] Ameziane-El-Hassani, R., Morand, S., Boucher, J.L., Frapart, Y.M., Apostolou, D., Agnandji, D., Gnidehou, S., Ohayon, R., Noel-Hudson, M.S., Francon, J., Lalaoui, K., Virion, A., Dupuy, C., Dual oxidase-2 has an intrinsic Ca2+-dependent H2O2-generating activity. J. Biol. Chem. 280:34 (2005), 30046–30054.
251. [250] Meitzler, J.L., Hinde, S., Banfi, B., Nauseef, W.M., Ortiz de Montellano, P.R., Conserved cysteine residues provide a protein-protein interaction surface in dual oxidase (DUOX) proteins. J. Biol. Chem. 288:10 (2013), 7147–7157.
252. [251] Xie, X., Hu, J., Liu, X., Qin, H., Percival-Smith, A., Rao, Y., Li, S.S., NIP/DuoxA is essential for Drosophila embryonic development and regulates oxidative stress response. Int. J. Biol. Sci. 6:3 (2010), 252–267.
253. [252] Qin, H., Percival-Smith, A., Li, C., Jia, C.Y., Gloor, G., Li, S.S., A novel transmembrane protein recruits numb to the plasma membrane during asymmetric cell division. J. Biol. Chem. 279:12 (2004), 11304–11312.
254. [253] Ostrakhovitch, E.A., Interplay between Numb and Notch in epithelial cancers: role for dual oxidase maturation factor. Eur. J. Cancer 45:12 (2009), 2071–2076.
255. [254] Huang, T., Zhou, Y., Cheng, A.S., Yu, J., To, K.F., Kang, W., NOTCH receptors in gastric and other gastrointestinal cancers: oncogenes or tumor suppressors?. Mol. Cancer, 15(1), 2016, 80.
256. [255] Nowell, C.S., Radtke, F., Notch as a tumour suppressor. Nat. Rev. Cancer 17:3 (2017), 145–159.
257. [256] Pancewicz-Wojtkiewicz, J., Epidermal growth factor receptor and notch signaling in non-small-cell lung cancer. Cancer Med. 5:12 (2016), 3572–3578.
258. [257] Sandiford, S.D., Kennedy, K.A., Xie, X., Pickering, J.G., Li, S.S., Dual oxidase maturation factor 1 (DUOXA1) overexpression increases reactive oxygen species production and inhibits murine muscle satellite cell differentiation. Cell Commun. Signal.: CCS, 12, 2014, 5.
259. [258] Ostrakhovitch, E.A., Semenikhin, O.A., p53-mediated regulation of neuronal differentiation via regulation of dual oxidase maturation factor 1. Neurosci. Lett. 494:1 (2011), 80–85.
260. [259] Kennedy, K.A., Ostrakhovitch, E.A., Sandiford, S.D., Dayarathna, T., Xie, X., Waese, E.Y., Chang, W.Y., Feng, Q., Skerjanc, I.S., Stanford, W.L., Li, S.S., Mammalian numb-interacting protein 1/dual oxidase maturation factor 1 directs neuronal fate in stem cells. J. Biol. Chem. 285:23 (2010), 17974–17985.
261. [260] Ostrakhovitch, E.A., Li, S.S.C., NIP1/DUOXA1 expression in epithelial breast cancer cells: regulation of cell adhesion and actin dynamics. Breast Cancer Res. Treat. 119:3 (2010), 773–786.
262. [261] Fahy, J., Jeltsch, A., Arimondo, P.B., DNA methyltransferase inhibitors in cancer: a chemical and therapeutic patent overview and selected clinical studies. Expert Opin. Ther. Pat. 22:12 (2012), 1427–1442.
263. [262] Harper, R.W., Xu, C., Eiserich, J.P., Chen, Y., Kao, C.Y., Thai, P., Setiadi, H., Wu, R., Differential regulation of dual NADPH oxidases/peroxidases, Duox1 and Duox2, by Th1 and Th2 cytokines in respiratory tract epithelium. FEBS Lett. 579:21 (2005), 4911–4917.
264. [263] Rada, B., Lekstrom, K., Damian, S., Dupuy, C., Leto, T.L., The Pseudomonas toxin pyocyanin inhibits the dual oxidase-based antimicrobial system as it imposes oxidative stress on airway epithelial cells. J. Immunol. 181:7 (2008), 4883–4893 (1950).
265. [264] Eskalli, Z., Achouri, Y., Hahn, S., Many, M.C., Craps, J., Refetoff, S., Liao, X.H., Dumont, J.E., Van Sande, J., Corvilain, B., Miot, F., De Deken, X., Overexpression of IL-4 in the thyroid of transgenic mice upregulates the expression of Duox1 and the anion transporter pendrin. Thyroid.: Off. J. Am. Thyroid. Assoc., 2016.
266. [265] Donko, A., Morand, S., Korzeniowska, A., Boudreau, H.E., Zana, M., Hunyady, L., Geiszt, M., Leto, T.L., Hypothyroidism-associated missense mutation impairs NADPH oxidase activity and intracellular trafficking of Duox2. Free Radic. Biol. Med. 73 (2014), 190–200.
267. [266] Liu, S., Zhang, W., Zhang, L., Zou, H., Lu, K., Li, Q., Xia, H., Yan, S., Ma, X., Genetic and functional analysis of two missense DUOX2 mutations in congenital hypothyroidism and goiter. Oncotarget, 2016.
268. [267] Park, W., Lee, H., Kim, E.H., Yoon, J.Y., Park, J.C., Shin, S.K., Lee, S.K., Lee, Y.C., Kim, W.H., Noh, S.H., Metabolic syndrome is an independent risk factor for synchronous colorectal neoplasm in patients with gastric neoplasm. J. Gastroenterol. Hepatol. 27:9 (2012), 1490–1497.
269. [268] Mu, G., Mu, X., Xing, H., Xu, R., Sun, G., Dong, C., Pan, Q., Xu, C., Subclinical hypothyroidism as an independent risk factor for colorectal neoplasm. Clin. Res. Hepatol. Gastroenterol. 39:2 (2015), 261–266.
270. [269] Tseng, F.Y., Lin, W.Y., Li, C.I., Li, T.C., Lin, C.C., Huang, K.C., Subclinical hypothyroidism is associated with increased risk for cancer mortality in adult Taiwanese-a 10 years population-based cohort. PLoS One, 10(4), 2015, e0122955.
271. [270] Lee, P.L., West, C., Crain, K., Wang, L., Genetic polymorphisms and susceptibility to lung disease. J. Negat. Results Biomed., 5, 2006, 5.
272. [271] Chen, S., Ling, Q., Yu, K., Huang, C., Li, N., Zheng, J., Bao, S., Cheng, Q.I., Zhu, M., Chen, M., Dual oxidase 1: a predictive tool for the prognosis of hepatocellular carcinoma patients. Oncol. Rep. 35:6 (2016), 3198–3208.